Research Catalog

Title

PET for drug development and evaluation / edited by D. Comar.

Publication

Dordrecht ; Boston : Kluwer Academic Publishers, [1995], ©1995.

Items in the Library & Off-site

Holdings

Details

Additional Authors

Comar, D.

Description

viii, 360 pages : illustrations (some color); 25 cm.

Series Statement

Developments in nuclear medicine ; v. 26

Uniform Title

Developments in nuclear medicine ; 26.

Subjects

• Tomography, Emission-Computed
• Tomography, Emission
• Drugs > Research > Methodology
• Drug Evaluation > methods
• Drug Design
• Drug Evaluation, Preclinical
• Drugs > Design

Bibliography (note)

• Includes bibliographical references.

Contents

• 1. Drug development and positron emission tomography / B. Campbell -- 2. Positron emission tomography: Basic principles and potential interest for pharmacological studies / B. Mazoyer -- 3. Is PET a tool for drug evaluation? / B. Langstrom, M. Bergstrom, P. Hartvig, S. Valind and Y. Watanabe -- 4. PET in neuropsychiatric drug development / L. Farde -- 5. Radioligand disposition and metabolism - Key information in early drug development / C. Halldin, C.-G. Swahn, L. Farde and G. Sevcall -- 6. PET studies in the early clinical development of a new antipsychotic / J. M. A. Sitsen and L. Farde -- 7. PET in the development of Dopamine D1 antagonists as new potential antipsychotic drugs / C. Foged, P. Karlsson, B. K. Skrumsager, L. Ynddal, E. B. Nielsen, C. Halldin and L. Farde --
• 8. Is the 5-HT[subscript 2]-receptor a target for antipsychotic drug action? PET studies on dopamine (D[subscript 2]) and serotonin (5-HT[subscript 2]) receptor occupancy in patients and healthy subjects / S. Nyberg, A.-L. Nordstrom, C. Halldin and L. Farde -- 9. Preclinical development of a radioligand for the study of central 5-HT[subscript 1A] receptors with PET-[11C]WAY - 100635 / V. W. Pike, I. A. Cliffe, A. Fletcher, S. P. Hume, J. A. McCarron, S. Ashworth, J. Opacka-Juffry, S. Osman, A. A. Lammertsma, K. G. Poole, A. C. White, C. J. Bench and P. Grasby -- 10. Comparative in vivo and in vitro selectivity of zolpidem for [omega] (Benzodiazepine) modulatory site subtypes / J. Benavides, P. Abadie, J. C. Baron and B. Scatton -- 11. Do the effects of muscarinic receptor blockade on brain glucose consumption mimic the cortical and subcortical metabolic pattern of Alzheimer's disease in normal volunteers? / J. Blin, T. N. Chase and M. F. Piercey --
• 12. PET evaluation of drug treatment in ischemic stroke and Alzheimer's disease / W.-D. Heiss -- 13. PET imaging of cerebral perfusion and oxygen metabolism in acute ischemic stroke: Implications for management and therapy / J. C. Baron -- 14. Pharmacokinetics: Kinetic modelling of MAO inhibitors and D[subscript 2] antagonists / A. Lammertsma and C. J. Bench -- 15. Brain activation under drug treatment / P. M. Grasby and K. J. Friston -- 16. Modifying the progression of Parkinson's disease / P. Morrish, J. Rakshi and D. J. Brooks -- 17. COMT inhibition: Pharmacology of tolcapone and 6-[[subscript 18]F]-Fluoro-L-Dopa (FDOPA) PET results / K. Jorga, K. L. Leenders, I. Gunther and M. Psylla -- 18. Interaction of Lisuride with dopaminergic receptors / B. Maziere and R. Horowski -- 19. Lisuride and [C-11]-raclopride interaction at the D2 receptor site / K. L. Leenders and A. Antonini -- 20. Drug design in cardiology: The pharmaceutical industry point of view / R. Gradnik --
• 21. Myocardial receptors and their interaction with cardiovascular drugs / A. Syrota and P. Merlet -- 22. The pathophysiological background of cardiovascular diseases and its impact on diagnosis and treatment / P. G. Camici -- 23. Effect of cardiotonic drugs on myocardial oxygen consumption and efficiency as assessed by [superscript 11]C-acetate and PET / L.-M. Voipio-Pulkki, H. Ukkonen, M. Saraste, J. Akkila and L. Lehtonen -- 24. Integration of new and classical techniques in drug development. PET application to Propionyl-L-carnitine pharmacokinetic study / A. Longo, F. Fiore, M. P. Law, A. Mancinelli, V. Pike and P. G. Camici -- 25. The view of the EORTC new drag development office on PET in (pre)clinical trials of anticancer drugs / H. R. Hendriks and J. Wanders -- 26. Bottlenecks in anticancer drug discovery and development: In vivo pharmacokinetic and pharmacodynamic issues and the potential role of PET / P. Workman --
• 27. Radiolabelled anticancer drugs for in vivo pharmacokinetic studies by PET / W. Vaalburg and F. Brady -- 28. The use of radiolabelled anticancer drugs in phase I/II clinical trials and the assessment of therapeutic efficacy of new agents using PET / P. Price, R. Harte, O. Tilsley, J. Matthews, F. Brady, S. Luthra, S. Osman, R. Babarovic, G. Brown, S. O'Reilly, C. Brock, P. Wells and T. Jones -- 29. Kinetics and applications of F-18-fluorouracil in colorectal tumors / L. G. Strauss -- 30. The disposition of a new drug propellant (HFA 134a) in humans studied by fluorine-18 labelling and whole-body [gamma]-counting / V. W. Pike, R. J. N. Tanner, F. I. Aigbirhio, C. A. J. Freemantle, S. L. Waters, B. C. Page, C. G. Rhodes, P. Olsson, G. P. Ventresca and T. Jones -- 31. Preclinical characterisation of radiolabelled idoxifene / P. Carnochan, H. Young, M. Trivedi, S. Eccles, B. Haynes and G. Potter.

ISBN

0792337166 (acid-free paper)

LCCN

95024830

Owning Institutions

Columbia University Libraries